The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
Clovis Oncology, Inc. Common Stock 189464100 4,631,347 101,855 SH   OTR   0 101,855 0
CymaBay Therapeutics, Inc. Common Stock 23257D103 14,072,225 1,048,601 SH   OTR   0 1,048,601 0
Achaogen, Inc. Common Stock 004449104 11,094,776 1,281,152 SH   OTR   0 1,281,152 0
Second Sight Medical Products, Inc. Common Stock 81362J100 7,458,339 4,492,975 SH   OTR   0 4,492,975 0
Ocular Therapeutix, Inc. Common Stock 67576A100 14,953,842 2,215,384 SH   OTR   0 2,215,384 0
Audentes Therapeutics, Inc. Common Stock 05070R104 46,028,339 1,204,615 SH   OTR   0 1,204,615 0
ImmuneDesign Corp. Common Stock 45252L103 10,047,356 2,208,210 SH   OTR   0 2,208,210 0
CRISPR Therapeutics AG Common Stock H17182108 212,057,436 3,608,874 SH   OTR   0 3,608,874 0
OpGen, Inc. Common Stock 68373L109 181,857 102,167 SH   OTR   0 102,167 0